CRISPR gene editing offers promising therapeutic possibilities for Duchenne Muscular Dystrophy (DMD) by addressing its genetic roots. This approach could lead to significant advancements in managing or potentially treating DMD. By focusing on the genetic cause, researchers aim to develop targeted therapies that improve outcomes for those affected.
The use of CRISPR in DMD represents a shift towards more precise treatments, enhancing the quality of life and potentially extending life expectancy for individuals with DMD. This emerging field holds considerable promise for effective treatments. As highlighted by Haque and Yokota (2025), this research marks an important step forward in treating DMD.
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks: